Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc. to explore additional ADC programs which leverage LCB’s proprietary ADC platform technology.   In April 2020, Iksuda licensed global development and commercialization rights for three ADC programs using LCB’s ADC linker/toxin platform. Under this expanded Agreement, Iksuda has...